WARREN, N.J., April 27, 2026 (Globe Newswire) — Tevogen (“Tevogen Bio Holdings Inc.” or the “Company”) (Nasdaq: TVGN) today announced continued progress in its artificial intelligence initiative Tevogen.AI, including near completion of the PredicTcell™ training algorithm and early steps toward commercialization readiness.
PredicTcell™, Tevogen.AI’s proprietary machine learning model designed to identify immunologically active peptides, is nearing the final stage of its training phase. The model is trained on one of the industry’s largest hand-picked peptide datasets and has been extended to over 180 parameters, contributing to an approximately 10% increase in accuracy.
As development progresses, we have begun evaluating potential co-development partnerships to support broader applications of the platform. These efforts are based on addressing a fundamental challenge in drug development: reliable target identification, which today often requires significant wet-lab validation. Tevogen.AI aims to reduce development schedules, material costs, and overall experiment burden by leveraging advanced predictive modeling.
To support this transition, Tevogen.AI has developed an initial version of an internal application and portal designed to deliver the PredicTcell™ model in a scalable and user-friendly environment. The system is intended to streamline internal workflows while also serving as the foundation for a future customer-facing platform.
Mittul Mehta, Chief Information Officer and Director, Tevogen.AI said: “As we begin to explore avenues of commercialization, we remain focused on maintaining scientific rigor while building scalable tools that can extend the impact of our platform beyond internal use.”
About Tevogen
Tevogen is a socially integrated healthcare company built on the principles of affordability, efficiency and scientific rigor. The company leverages artificial intelligence and precision T-cell therapy platforms, a patient-first, cost-disciplined operating model, and collaborations with global technology leaders to support the development of advanced life-saving treatments across multiple therapeutic areas and scalable solutions for the broader health system.
The company’s flagship initiative, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of single-HLA-restricted, genetically unmodified, allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology and neurology, and its programs are built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, reducing failure rates, and supporting optimized clinical trial design through proprietary predictive technology. The platform leverages cloud and data services from leading technology providers such as Microsoft and Databricks to advance the long-term goal of predicting the proteome of specific protein and HLA combinations, enabling rapid and cost-effective treatment discovery.
Tevogen is exploring future strategic initiatives including domestic generic drugs, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to drive sustainable innovation and expand patient access through faster, more efficient and more equitable care models.
Forward-looking statements
This press release contains certain forward-looking statements, including, without limitation, statements relating to: POTENTIAL TRANSACTIONS AND POTENTIAL ADVANTAGES OF TRANSACTIONS. plans for Tevogen’s research and manufacturing capabilities; Expectations for future growth. Expectations for the Healthcare and Biopharmaceutical Industry. the development of Tevogen’s product candidates for the treatment of infectious diseases and cancer, their potential benefits and patient access; Forward-looking statements may be identified by words such as “may,” “might,” “will,” “expect,” “anticipate,” “could,” “potential,” “goal,” “opportunity,” “anticipate,” “believe,” “future” or similar words or expressions, or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors, including known and unknown risks, delays, uncertainties and other factors beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: the risk that the transaction may not be completed on favorable terms or at all; the risk that the expected benefits of a transaction may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including the competitive environment, technological advances and regulatory changes; changes in general economic conditions domestically and worldwide; the risk that Tevogen may be unable to implement its growth strategies or may have difficulty managing growth or expanding its operations; the risk that Tevogen may be unable to develop and maintain effective internal controls; failure to achieve Tevogen’s commercialization and development plans and to identify and realize additional opportunities; These opportunities may be affected by, among other things, competition, Tevogen’s ability to grow economically and manage growth, and hire and retain key employees. the risk that Tevogen may not be able to keep pace with rapid technological developments to offer new and innovative products and services or make significant investments in new products and services that are not successful; Tevogen’s need to raise additional capital to fully realize its business plans; risks related to our ability to develop, license and obtain new treatments; the risk of regulatory litigation or proceedings relating to Tevogen’s business; uncertainties associated with the conduct, cost and completion of preclinical studies and clinical trials; risks associated with regulatory review, approval and commercial development; risks related to intellectual property protection; Tevogen’s operating history is limited. These factors are discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date on which they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
contact
Tevogen Bio Communications
Phone number: 1 877 TEVOGEN, extension 701
Communications@Tevogen.com
Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dc577aeb-e6dd-4eaa-ba5e-c5b1cac3e0b0.
